

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

THE GROUP'S "PREGABALIN CAPSULES" WAS GRANTED THE U.S. ANDA APPROVAL

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Abbreviated New Drug Application ("**ANDA**") of the Group's product "Pregabalin Capsules" has been granted approval by the U.S. Food and Drug Administration.

Pregabalin is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), which can block voltage-dependent calcium channels and reduce the release of neurotransmitters. Clinically, it is mainly used for painful diabetic peripheral neuropathy, post-herpetic neuralgia, adjuvant treatment for partial onset seizures in adult patients with epilepsy, generalized anxiety disorder, spinal cord injury nerve pain and fibromyalgia.

Currently, the Group has 19 products with ANDA approval obtained. This approval further signifies the Group's research and development and quality control have reached advanced international standard.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 30 December 2019

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.